Patient characteristics (n=75)
| First time point | Second time point | 6 month change | p–value# | |
| Age years | 69.9±8.7 | |||
| Male | 64 (85.3%) | |||
| Current/previous/never smoker | 7 (9.3%)/62 (82.7%)/6 (8.0%) | |||
| Biopsy-proven | 16 (21.3%) | |||
| Treated with pirfenidone | 11 (14.7%) | 27 (36.0%) | ||
| Treated with CS and/or IS | 13 (17.3%) | 15 (20.0%) | ||
| FVC % predicted | 87.5±20.4¶ | 86.3±22.3¶ | −1.2±0.8 | 0.21 |
| DLCO % predicted | 43.5±11.1+ | 41.1±13.2+ | −2.4±0.8 | <0.01 |
| CPI | 47.4±10.7+ | 49.2±13.0+ | 1.7±0.7 | 0.03 |
| Serum KL-6 U·mL−1 | 1121±733 | 1251±889 | 131±63 | 0.06 |
| Serum SP-D ng·mL−1 | 302±224 | 308±240 | 7±18 | 0.71 |
Data are presented as mean±sd unless otherwise stated. CS: corticosteroid; IS: immunosuppressive agent; FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide; CPI: composite physiologic index. #: comparisons between the first and second time points using the Wilcoxon matched-pairs signed-ranks test; KL-6: Krebs von den Lungen-6; SP-D: surfactant protein-D. ¶: n=57, a subject was included if FVC data were available at both time points; +: n=56, a subject was included if DLCO and CPI data were available at both time points.